Merck plots FDA app as sleep drug aces new trial

Armed with new Phase III data on its potential sleep drug suvorexant, Merck ($MRK) plans to ask FDA to approve the new product later this year. One big selling point: 90% of patients didn't feel sleepy the next day. Report